I just recently listened to a webinar where David (Dedi) Meiri spoke about the cannabis research in his lab at the Technion-Israel Institute of Innovation. Meiri is best understood for his work matching particular components of cannabis to impact different types of cancer. When the job interviewer asked the Israeli researcher which areas of medication he thought marijuana offered the most guarantee, the answer was surprising.
On top of what is currently known and dealt with … pain, sleep, epilepsy, stress and anxiety and these kinds of things, I think that one of the things that is still not being treated with cannabis … and I really, truly think in it, and in my laboratory I have phenomenal results, is dementia and Alzheimer’s.
There is a large and growing body of anecdotal accounts of the effectiveness of cannabis for dealing with the signs of Alzheimer’s disease and dementia. The drawbacks and real lethal threats associated with standard and regularly recommended pharmaceutical treatments for these conditions makes marijuana an especially compelling choice– particularly considering its solid safety profile.
In a follow up Zoom call, Dedi spoke about his deal with this topic:
First of all, cannabis is very useful in improving quality of life: minimizing anxiety, enhancing sleep, minimizing violence. We understand it from our work with autistic children, from treating PTSD, and other indications. We currently know which pressures are achieving this result and a great deal of them are high CBD stress, with extremely low or no THC. Autistic kids in Israel are getting a strain extract with a really low quantity of THC and it still decreases violence, really enhances sleep and minimizes anxiety.
If we’re discussing enhancing quality of life of the Alzheimer’s client and their households … individuals with Alzheimer’s typically struggle with bursts of anger and sleep disorders. On that scale marijuana is extremely useful …
However Meiri also mentions that for Alzheimer’s illness, like with cancer, marijuana might also have a function beyond palliative care. Simply as his lab takes a look at the various chemovars and combinations of cannabinoids that can potentially detain cancer development, they are investigating the neuroprotective performance of these compounds also.
With Alzheimer’s, on top of all the palliative treatment on the lifestyle, there is a concern whether cannabis can also actually fight the dementia or improve the memory or the pathology of the illness itself. There are already a couple of research studies that have actually revealed that marijuana in low dosages can be efficient. It’s understood that the endocannabinoid system is involved in this procedure and in the progression of Alzheimer’s. So, decrease of Anandamide and 2AG and other endocannabinoids is in line with the development of the disease.
Over the last three years, Meiri has been pursuing this line of research study using mouse and other Alzheimer’s disease models.
We screened a great deal of marijuana chemovars and specified a few that are minimizing the amyloid plaques in the brain. We likewise identified the systems that are triggered in the brain, how this occurs, and why they are decreasing the plaques. We have really strong outcomes showing improvement in the pathology of the disease in mice with rather advanced Alzheimer’s after treatment with specific particles of marijuana. This includes improvements in the damage from the amyloid plaques in the brain and the nerve cells that were treated with the specific marijuana particles, along with enhancement in their behavior as evidenced through numerous tests.
However, there is a large space in between the mice brain and the human brain, so I couldn’t tell you if it will work in human clients …
To get rid of that space, Meiri and his group are now in the procedure of getting approvals for a clinical trial to check the results of a complete spectrum cannabis extract on patients.
It’s a scientific trial on around 80 clients who suffer from serious Alzheimer’s disease, with violent habits, anxiety, anger and sleep disorders. We will treat them with cannabis to see if it can improve their habits, make them calmer, more unwinded and help them sleep much better. This is cannabis with an extremely low amount of THC or without THC at all– a whole extract of a high CBD stress. It’s not simply sedation – you do not give them THC and get them stoned and they’re just lying on the sofa. It’s not that. It’s other substances and other effects.
We also discussed the essential subtleties in between marijuana cultivars, and the need of looking beyond just THC and CBD.
We have cultivars that are improving an illness considerably, and we have cultivars that make the illness even worse, even though they have the same amount of CBD and THC. It’s true for sleep disorders, multiple sclerosis, in Alzheimer’s and with a cancer.
If that holds true, then what about all the marijuana medicines that are simply made up of THC and CBD isolates in various ratios?
I guess for specific indications, like pain, for instance, it might be enough. In a lot of the indications, it will not be enough. I can inform you that if you look at leukemia, what we find is that if you simply treat it with CBD you will get zero response. The exact same opts for numerous sclerosis, Alzheimer’s and even breast cancer … I have at least six different examples that I currently showed that it’s not the THC/CBD ratios, or it’s not enough. I can’t state that about whatever, but for sure in these kinds of indicators.
So after dismissing simply CBD and THC, I asked him, what does he presume is making the difference?
I am 100%sure it’s not the THC and CBD due to the fact that I already eliminated them … however I’m still not actually sure about the rest. I’m presuming that the flavonoids might be playing a big role there … Just a couple of cannabinoids or households of cannabinoids, however mainly probably flavonoids and terpenoids – offer me a few more months and then I’ll tell you.